Navigation Links
New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine

, 990.8) for anti-HPV 11, 3056.9 (95% CI: 2594.4, 3601.8) for anti-HPV 16, and 527.2 (95% CI: 450.9, 616.5) for anti-HPV 18. The GMTs for women who did not nurse during vaccine administration were 540.1 (95% CI: 523.5, 557.2) for anti-HPV 6, 746.3 (95% CI: 720.4, 773.3) for anti-HPV 11, 2290.8 (95% CI: 2180.7, 2406.3) for anti-HPV 16, and 456.0 (95% CI: 438.4, 474.3) for anti-HPV 18. Overall, 17 and 9 infants of subjects who received GARDASIL or placebo, respectively (representing 3.4% and 1.8% of the total number of subjects who were breast-feeding during the period in which they received GARDASIL or placebo, respectively), experienced a serious adverse experience. None was judged by the investigator to be vaccine related. In clinical studies, a higher number of breast-feeding infants (n = 6) whose mothers received GARDASIL had acute respiratory illnesses within 30 days post-vaccination of the mother as compared to infants (n = 2) whose mothers received placebo. In these studies, the rates of other adverse experiences in the mother and the nursing infant were comparable between vaccination groups. Pediatric Use The safety and efficacy of GARDASIL have not been evaluated in children younger than 9 years. Geriatric Use The safety and efficacy of GARDASIL have not been evaluated in adults above the age of 26 years. ADVERSE REACTIONS In 5 clinical trials (4 placebo-controlled), subjects were administered GARDASIL or placebo on the day of enrollment, and approximately 2 and 6 months thereafter. Few subjects (0.1%) discontinued due to adverse experiences. In all except 1 of the clinical trials, safety was evaluated using vaccination report card (VRC)-aided surveillance for 14 days after each injection of GARDASIL or placebo. The subjects who were monitored using VRC-aided surveillance included 5088 girls and women 9 through 26 years of age at enrollment who received GARDASIL and 3790 girls and women who receive
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "PCSK9 and Other Novel Hypercholesterolemia Drugs" ... indicate that there is a high cholesterol burden despite ... Out of all the available options, statins have been ... concluded that reduction of plasma LDL cholesterol (LDLC) is ...
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... and fiscal 2014 ended July 31, 2014 on Monday, September ... to discuss the results at 11:00 AM ET. Participating in ... Andrew A. Krakauer , President and CEO; Jorgen ... A. Sheldon , Senior Vice President, CFO and Treasurer; and ...
Breaking Medicine Technology:PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2
... N.J., Oct. 15 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., has received approval from the United States ... Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and ... The ANDA was acquired as part of Watson,s acquisition ...
... Inc. (Nasdaq: REGN ) will webcast its ... Industry Conference on Friday, October 22, 2010.  The presentation ... may be accessed through the Company,s web site, ... version of the presentation will be available after the ...
Cached Medicine Technology:Watson's Generic Version of Lotrel ® Receives FDA Approval 2
(Date:9/22/2014)... new study pulls back the curtain on one of ... payment and income between physicians who perform operations, procedures ... to perception, the research indicates, the physician payment system ... procedure-performing doctors. , The new findings counter the widely ... minute explains why doctors who perform procedures often earn ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 (HealthDay ... care units (NICU) set up private rooms for parents to ... Researchers at one children,s hospital found that preemies gained weight ... NICU switched from the traditional "open-bay" layout to private rooms ... the journal Pediatrics , add to evidence that private ...
(Date:9/22/2014)... Up to 40 percent of patients undergoing breast cancer ... remove all the cancerous tissue in the initial operation. ... successfully tested a tool they developed that will help ... thereby decreasing the chances for repeat operations. ... of September 22, 2014 in the Proceedings of ...
(Date:9/22/2014)... ON (September 22, 2014) McMaster scientists have found ... new class of antibiotics. , Although dozens of ... at how a certain part of bacteria are created, ... it. , The discovery is important as there ... making the cures for infections ineffective. The World Health ...
(Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:The fine line between breast cancer and normal tissues 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2
... MONDAY, Jan. 16 (HealthDay News) -- Persistent pain, eating problems ... survivors of head and neck cancer, a new study finds. ... issue of the journal Archives of Otolaryngology -- Head ... were diagnosed with head and neck cancer from 1995 to ...
... ten Canadians cannot afford to take their prescription drugs as ... of British Columbia and the University of Toronto. ... Canadian Medical Association Journal ) is the first to examine ... drugs in Canada. Researchers from UBC,s Centre for Health Services ...
... most severe cases of Lupus (systemic lupus erythemathosus), an ... the activity of some critical genes of the immune ... Italian researchers at the Catholic University of Sacred Heart ... the accelerator of the car and boosts the pathological ...
... British Columbia have found a new way to block infection ... could lead to new therapies for those affected by this ... worldwide suffer from hepatitis C, the disease caused by chronic ... of the leading causes of liver cancer and liver transplant ...
... Scientists working at the Medical Research Council have identified ... pre-cancerous cells in the esophagus, a condition called Barrett,s ... these cells before they develop into esophageal cancer. These ... have important implications for patients and may help to ...
... -- Soccer players need to use the correct techniques ... redirect the ball -- to prevent possible brain injury, researchers ... between the sport and brain damage, Dr. Alejandro Spiotta and ... moving at high speeds when they come into contact with ...
Cached Medicine News:Health News:Many Head and Neck Cancer Survivors Face Eating Problems 2Health News:1 in 10 Canadians cannot afford prescription drugs: UBC study 2Health News:A genetic accelerator hits the gas on autoimmune diseases 2Health News:UBC researchers identify potential new therapy approach for hepatitis C 2Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:Heading Soccer Balls Could Injure Brain 2
... new thinking to address common problems associated ... mm diameter outer arthroscope sheath, the shorter, ... Videoscope has superior access and mobility in ... and especially in the elbow and ankle. ...
... is the second generation of the lens ... technology allows one-handed delivery of the C11UB ... colored plunger allows better visualization and is ... insertion. The modified 55-degree beveled tip eases ...
... Heart 2006 is a long-term Transtelephonic ... This device is the solution ... symptoms and their correlation to the ... it provides 2 lead loop recording ...
... cable and 4 metal chest electrodes ... 3-step procedure enabling a patient to ... lead ECG through a simple change ... seconds per lead and 10 seconds ...
Medicine Products: